Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: Trial data and implications for clinical management
Chandra Belani
, Thomas Lynch
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Cancer Institute, Next-Generation Therapies
Research output
:
Contribution to journal
›
Review article
›
peer-review
22
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: Trial data and implications for clinical management'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Cancer Clinical Trials
100%
Clinical Management
100%
Docetaxel
100%
Taxotere
100%
Trial Data
100%
Cisplatin
50%
Neutropenia
33%
Response Rate
33%
Carboplatin
33%
Adverse Events
16%
Phase II Study
16%
Clinically Significant
16%
New Combination
16%
Area under the Curve
16%
France
16%
Neurotoxicity
16%
Phase II Trial
16%
Accruals
16%
Nephrotoxicity
16%
Randomized Phase III Trial
16%
Survival Median
16%
Severe Neuropathy
16%
First-line Regimen
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Docetaxel
100%
Cisplatin
37%
Carboplatin
25%
Neutropenia
25%
Adverse Event
12%
Neuropathy
12%
Neurotoxicity
12%
Phase II Trials
12%
Nephrotoxicity
12%